These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 1726492

  • 1. Intensive treatment of stage III-IV aggressive malignant lymphomas (protocol TPL-84).
    Colombat P, Guilhot F, Bordesoule D, Renou P, Benz-Lemoine E, Fouillard L, Drouet M, Tanzer J, Lamagnere JP.
    Haematologica; 1991; 76(6):479-84. PubMed ID: 1726492
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M.
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [Abstract] [Full Text] [Related]

  • 3. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
    Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci ML, Bibi Triki T, Hennequin C, Fermé C, Gisselbrecht C.
    Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678
    [Abstract] [Full Text] [Related]

  • 4. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P, Cornillet P, Deconinck E, Tourani JM, Gardembas M, Delain M, Abgrall JF, Kootz C, Milpied N.
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [Abstract] [Full Text] [Related]

  • 5. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 6. [Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol].
    Ribera JM, Grañena A, Rozman C, Urbano-Ispizua A, Bladé J, Carreras E, Cervantes F, Marín P, Sierra J, Nomdedeu B.
    Sangre (Barc); 1990 Feb; 35(1):26-32. PubMed ID: 2333581
    [Abstract] [Full Text] [Related]

  • 7. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 8. Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897).
    Todeschini G, Tecchio C, Pasini F, Benedetti F, Cantini M, Crippa C, Draisci M, Pizzolo G.
    Cancer; 2005 Aug 01; 104(3):555-60. PubMed ID: 15959910
    [Abstract] [Full Text] [Related]

  • 9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 10. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD, Wolff SN, Stein RS, Greer JP, Cousar JB, Greco FA.
    Cancer Treat Rep; 1986 Aug 01; 70(8):953-8. PubMed ID: 3015406
    [Abstract] [Full Text] [Related]

  • 11. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
    Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E, Lauta VM, De Renzo A, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S.
    Haematologica; 1999 Nov 01; 84(11):996-1001. PubMed ID: 10553159
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V.
    Haematologica; 1998 Sep 01; 83(9):800-11. PubMed ID: 9825577
    [Abstract] [Full Text] [Related]

  • 13. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A, Fruchart C, Bastit D, Boulet D, Moncondult M, Piguet H, Tilly H.
    Cancer; 1996 Jun 01; 77(11):2302-7. PubMed ID: 8635099
    [Abstract] [Full Text] [Related]

  • 14. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group.
    J Clin Oncol; 2005 Jun 01; 23(16):3793-801. PubMed ID: 15809447
    [Abstract] [Full Text] [Related]

  • 15. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.
    Cancer Invest; 2008 May 01; 26(4):401-6. PubMed ID: 18443961
    [Abstract] [Full Text] [Related]

  • 16. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
    Bone Marrow Transplant; 1996 Feb 01; 17(2):149-55. PubMed ID: 8640159
    [Abstract] [Full Text] [Related]

  • 17. The F-MACHOP regimen in the treatment of aggressive non-Hodgkin's lymphomas: a single center experience in 72 patients.
    Infanti L, Silvestri F, Fanin R, Salmaso F, Zaja F, Barillari G, Patriarca F, Geromin A, Cerno M, Damiani D, Baccarani M.
    Haematologica; 1996 Feb 01; 81(6):521-8. PubMed ID: 9009439
    [Abstract] [Full Text] [Related]

  • 18. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 19. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G, Butti C, Baldini L, Ceriani A, Lombardi F, Luoni M, Montalbetti L, Pavia G, Pinotti G, Pogliani E.
    Haematologica; 1995 May 01; 80(4):318-24. PubMed ID: 7590500
    [Abstract] [Full Text] [Related]

  • 20. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.
    Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G.
    N Engl J Med; 1997 May 01; 336(18):1290-7. PubMed ID: 9113932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.